TY - JOUR
T1 - First national surveillance of susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel
AU - Colodner, Raul
AU - Samra, Zmira
AU - Keller, Nathan
AU - Sprecher, Hanna
AU - Block, Colin
AU - Peled, Nehama
AU - Lazarovitch, Tzilia
AU - Bardenstein, Rita
AU - Schwartz-Harari, Orna
AU - Carmeli, Yehuda
PY - 2007/2/1
Y1 - 2007/2/1
N2 - In this 1st national surveillance study, the susceptibility pattern of 1011 consecutive isolates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. isolated from patients hospitalized in Israel hospitals, covering 62.3% of all general hospital beds in the country, was investigated. Proportion of susceptibilities (range among institutions, MIC50/MIC90 in micrograms per milliliter) were to ertapenem 95.0% (88.8-100%, 0.19/0.75), imipenem 98.8% (88.8-100%, 0.25/0.38), meropenem 98.2% (90.0-100%, 0.06/0.19), piperacillin-tazobactam 59.1% (42.6-77.0%, 16/256), ciprofloxacin 17.2% (9.0-24.6%, 32/32), levofloxacin 17.8% (9.0-24.6%, 32/32), amikacin 74.5% (63.8-98.0%, 6/32), and gentamicin 19.3% (12.3-28.5%, 96/256). Coresistance, cross-resistance, and variability between institutions were high. Only carbapenems retain predicted activity against ESBL-producing E. coli and Klebsiella spp. across Israeli hospitals.
AB - In this 1st national surveillance study, the susceptibility pattern of 1011 consecutive isolates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. isolated from patients hospitalized in Israel hospitals, covering 62.3% of all general hospital beds in the country, was investigated. Proportion of susceptibilities (range among institutions, MIC50/MIC90 in micrograms per milliliter) were to ertapenem 95.0% (88.8-100%, 0.19/0.75), imipenem 98.8% (88.8-100%, 0.25/0.38), meropenem 98.2% (90.0-100%, 0.06/0.19), piperacillin-tazobactam 59.1% (42.6-77.0%, 16/256), ciprofloxacin 17.2% (9.0-24.6%, 32/32), levofloxacin 17.8% (9.0-24.6%, 32/32), amikacin 74.5% (63.8-98.0%, 6/32), and gentamicin 19.3% (12.3-28.5%, 96/256). Coresistance, cross-resistance, and variability between institutions were high. Only carbapenems retain predicted activity against ESBL-producing E. coli and Klebsiella spp. across Israeli hospitals.
KW - β-Lactamase
KW - Escherichia coli
KW - Israel
UR - http://www.scopus.com/inward/record.url?scp=33846509415&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2006.07.011
DO - 10.1016/j.diagmicrobio.2006.07.011
M3 - Article
C2 - 17258084
AN - SCOPUS:33846509415
SN - 0732-8893
VL - 57
SP - 201
EP - 205
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 2
ER -